JP2023546226A - 統合ストレス応答経路のモジュレーター - Google Patents
統合ストレス応答経路のモジュレーター Download PDFInfo
- Publication number
- JP2023546226A JP2023546226A JP2023524308A JP2023524308A JP2023546226A JP 2023546226 A JP2023546226 A JP 2023546226A JP 2023524308 A JP2023524308 A JP 2023524308A JP 2023524308 A JP2023524308 A JP 2023524308A JP 2023546226 A JP2023546226 A JP 2023546226A
- Authority
- JP
- Japan
- Prior art keywords
- trifluoromethoxy
- ethoxy
- oxadiazol
- piperidine
- tert
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Electrochromic Elements, Electrophoresis, Or Variable Reflection Or Absorption Elements (AREA)
- Amplifiers (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP20203311 | 2020-10-22 | ||
| EP20203311.4 | 2020-10-22 | ||
| EP21192154.9 | 2021-08-19 | ||
| EP21192154 | 2021-08-19 | ||
| PCT/EP2021/079209 WO2022084447A1 (en) | 2020-10-22 | 2021-10-21 | Modulators of the integrated stress response pathway |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2023546226A true JP2023546226A (ja) | 2023-11-01 |
| JP2023546226A5 JP2023546226A5 (https=) | 2024-10-28 |
Family
ID=78402117
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023524308A Pending JP2023546226A (ja) | 2020-10-22 | 2021-10-21 | 統合ストレス応答経路のモジュレーター |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20230391763A1 (https=) |
| EP (1) | EP4232447A1 (https=) |
| JP (1) | JP2023546226A (https=) |
| KR (1) | KR20230110510A (https=) |
| AU (1) | AU2021363616B2 (https=) |
| CA (1) | CA3195292A1 (https=) |
| IL (1) | IL302219A (https=) |
| MX (1) | MX2023004677A (https=) |
| WO (1) | WO2022084447A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2022011143A (es) | 2020-03-11 | 2022-10-13 | Evotec Int Gmbh | Moduladores de la via de respuesta integrada al estres. |
| WO2024109736A1 (zh) * | 2022-11-21 | 2024-05-30 | 深圳众格生物科技有限公司 | 一种化合物、包含其的药物组合物及其合成方法和用途 |
Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019032743A1 (en) * | 2017-08-09 | 2019-02-14 | Denali Therapeutics Inc. | COMPOUNDS, COMPOSITIONS AND METHODS |
| WO2019046779A1 (en) * | 2017-09-01 | 2019-03-07 | Denali Therapeutics Inc. | COMPOUNDS, COMPOSITIONS AND METHODS |
| WO2019090082A1 (en) * | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| JP2019521111A (ja) * | 2016-06-08 | 2019-07-25 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ａｔｆ４経路阻害剤としての化学化合物 |
| WO2020168011A1 (en) * | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| WO2020216766A1 (en) * | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| WO2020216764A1 (en) * | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| WO2020223538A1 (en) * | 2019-04-30 | 2020-11-05 | Calico Life Sciences Llc | Substituted cycloalkyls as modulators of the integrated stress pathway |
| WO2021151865A1 (en) * | 2020-01-28 | 2021-08-05 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| WO2021180774A1 (en) * | 2020-03-11 | 2021-09-16 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
Family Cites Families (32)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6806562B2 (ja) | 2013-03-15 | 2021-01-06 | ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア | ｅＩＦ２α経路の調節因子 |
| TW201808888A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808914A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TW201808903A (zh) | 2016-05-05 | 2018-03-16 | 嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| TWI763668B (zh) | 2016-05-05 | 2022-05-11 | 美商嘉來克生命科學有限責任公司 | 整合應激途徑之調節劑 |
| AU2017279027A1 (en) | 2016-06-08 | 2018-12-20 | Glaxosmithkline Intellectual Property Development Limited | Chemical Compounds |
| US10815222B2 (en) * | 2016-12-23 | 2020-10-27 | C.N.C.C.S. S.C.A.R.L. Collezione Nazionale Dei Composti Chimici E Centro Screening | Compounds for use in the treatment of kinetoplastid infection |
| WO2018225093A1 (en) | 2017-06-07 | 2018-12-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds as atf4 pathway inhibitors |
| US20210145771A1 (en) | 2017-07-03 | 2021-05-20 | Glaxosmithkline Intellectual Property Development Limited | N-(3-(2-(4-chlorophenoxy)acetamido)bicyclo[1.1.1] pentan-1-yl)-2-cyclobutane-1- carboxamide derivatives and related compounds as atf4 inhibitors for treating cancer and other diseases |
| CN110896634A (zh) | 2017-07-03 | 2020-03-20 | 葛兰素史密斯克莱知识产权发展有限公司 | 作为atf4抑制剂用于治疗癌症和其它疾病的2-(4-氯苯氧基)-n-((1-(2-(4-氯苯氧基)乙炔氮杂环丁烷-3-基)甲基)乙酰胺衍生物和相关化合物 |
| US11939320B2 (en) | 2017-11-02 | 2024-03-26 | Abbvie Inc. | Modulators of the integrated stress pathway |
| SG11202004009TA (en) | 2017-11-02 | 2020-05-28 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| EP3704098B1 (en) | 2017-11-02 | 2024-01-24 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| CA3080804A1 (en) | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| UY37958A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| EP3704125B1 (en) | 2017-11-02 | 2026-03-11 | Calico Life Sciences LLC | Modulators of the integrated stress pathway |
| UY37957A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| UY37956A (es) | 2017-11-02 | 2019-05-31 | Abbvie Inc | Moduladores de la vía de estrés integrada |
| WO2019118785A2 (en) | 2017-12-13 | 2019-06-20 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| WO2019183589A1 (en) | 2018-03-23 | 2019-09-26 | Denali Therapeutics Inc. | Modulators of eukaryotic initiation factor 2 |
| WO2019193540A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Heteroaryl derivatives of formula (i) as atf4 inhibitors |
| WO2019193541A1 (en) | 2018-04-06 | 2019-10-10 | Glaxosmithkline Intellectual Property Development Limited | Bicyclic aromatic ring derivatives of formula (i) as atf4 inhibitors |
| WO2019236710A1 (en) | 2018-06-05 | 2019-12-12 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| JP2021529814A (ja) | 2018-07-09 | 2021-11-04 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | 化学化合物 |
| WO2020031107A1 (en) | 2018-08-08 | 2020-02-13 | Glaxosmithkline Intellectual Property Development Limited | Chemical compounds |
| TWI877863B (zh) | 2018-10-11 | 2025-03-21 | 美商嘉來克生命科學有限責任公司 | 整合應激路徑之前藥調節劑 |
| US12091392B2 (en) | 2019-02-13 | 2024-09-17 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| US20200270232A1 (en) | 2019-02-25 | 2020-08-27 | Praxis Biotech LLC | Inhibitors of integrated stress response pathway |
| US20220177456A1 (en) | 2019-03-06 | 2022-06-09 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| AR118836A1 (es) | 2019-04-30 | 2021-11-03 | Calico Life Sciences Llc | Moduladores de la vía de tensión integrada |
| MX2021015210A (es) | 2019-06-12 | 2022-01-18 | Praxis Biotech LLC | Inhibidores de la via de respuesta al estres integrada. |
| JP2022536663A (ja) | 2019-06-12 | 2022-08-18 | プラクシス バイオテック エルエルシー | 統合的ストレス応答経路のモジュレーター |
-
2021
- 2021-10-21 US US18/033,312 patent/US20230391763A1/en active Pending
- 2021-10-21 MX MX2023004677A patent/MX2023004677A/es unknown
- 2021-10-21 WO PCT/EP2021/079209 patent/WO2022084447A1/en not_active Ceased
- 2021-10-21 KR KR1020237016361A patent/KR20230110510A/ko active Pending
- 2021-10-21 AU AU2021363616A patent/AU2021363616B2/en active Active
- 2021-10-21 IL IL302219A patent/IL302219A/en unknown
- 2021-10-21 JP JP2023524308A patent/JP2023546226A/ja active Pending
- 2021-10-21 CA CA3195292A patent/CA3195292A1/en active Pending
- 2021-10-21 EP EP21798643.9A patent/EP4232447A1/en active Pending
Patent Citations (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2019521111A (ja) * | 2016-06-08 | 2019-07-25 | グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ | Ａｔｆ４経路阻害剤としての化学化合物 |
| WO2019032743A1 (en) * | 2017-08-09 | 2019-02-14 | Denali Therapeutics Inc. | COMPOUNDS, COMPOSITIONS AND METHODS |
| WO2019046779A1 (en) * | 2017-09-01 | 2019-03-07 | Denali Therapeutics Inc. | COMPOUNDS, COMPOSITIONS AND METHODS |
| WO2019090082A1 (en) * | 2017-11-02 | 2019-05-09 | Calico Life Sciences Llc | Modulators of the integrated stress pathway |
| WO2020168011A1 (en) * | 2019-02-13 | 2020-08-20 | Denali Therapeutics Inc. | Compounds, compositions and methods |
| WO2020216766A1 (en) * | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| WO2020216764A1 (en) * | 2019-04-23 | 2020-10-29 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| WO2020223538A1 (en) * | 2019-04-30 | 2020-11-05 | Calico Life Sciences Llc | Substituted cycloalkyls as modulators of the integrated stress pathway |
| WO2021151865A1 (en) * | 2020-01-28 | 2021-08-05 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
| WO2021180774A1 (en) * | 2020-03-11 | 2021-09-16 | Evotec International Gmbh | Modulators of the integrated stress response pathway |
Non-Patent Citations (1)
| Title |
|---|
| 野崎 正勝 他, 創薬化学, vol. 第1版, JPN7023001664, 1995, JP, pages 98 - 99, ISSN: 0005802217 * |
Also Published As
| Publication number | Publication date |
|---|---|
| KR20230110510A (ko) | 2023-07-24 |
| WO2022084447A1 (en) | 2022-04-28 |
| AU2021363616A1 (en) | 2023-06-22 |
| IL302219A (en) | 2023-06-01 |
| CA3195292A1 (en) | 2022-04-28 |
| US20230391763A1 (en) | 2023-12-07 |
| AU2021363616A9 (en) | 2025-04-03 |
| MX2023004677A (es) | 2023-05-24 |
| AU2021363616B2 (en) | 2026-03-26 |
| EP4232447A1 (en) | 2023-08-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP7590343B2 (ja) | 統合ストレス応答経路のモジュレーター | |
| JP7588089B2 (ja) | 統合ストレス応答経路のモジュレーター | |
| JP7699595B2 (ja) | 統合的ストレス応答経路の調節因子 | |
| JP2023517944A (ja) | 統合的ストレス応答経路の調節因子 | |
| JP2023546226A (ja) | 統合ストレス応答経路のモジュレーター | |
| JP2023546224A (ja) | 統合ストレス応答経路のモジュレーター | |
| JP7851926B2 (ja) | 統合ストレス応答経路のモジュレーター | |
| EA051483B1 (ru) | Модуляторы пути интегрированного ответа на стресс | |
| CN116761803A (zh) | 整合应激反应途径的调节剂 | |
| HK40100736A (zh) | 整合应激反应途径的调节剂 | |
| EA048763B1 (ru) | Модулятор пути интегрированного ответа на стресс и его применение | |
| EA050793B1 (ru) | Модуляторы пути интегрированного ответа на стресс | |
| EA051407B1 (ru) | Модуляторы пути интегрированного ответа на стресс | |
| HK40100236A (zh) | 整合应激反应途径的调节剂 | |
| HK40073491A (en) | Modulators of the integrated stress response pathway | |
| HK40068816A (en) | Modulators of the integrated stress response pathway | |
| HK40068295A (en) | Modulators of the integrated stress response pathway | |
| EA048846B1 (ru) | Модуляторы пути интегрированного ответа на стресс | |
| HK40100739A (zh) | 整合应激反应途径的调节剂 | |
| HK40073491B (zh) | 整合应激反应途径的调节剂 | |
| HK40068295B (zh) | 整合应激反应途径的调节剂 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20241018 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20241018 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20250815 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20250819 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20251114 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20260224 |